These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

889 related items for PubMed ID: 25514100

  • 1. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
    Moran C, Arriaga M, Arechavaleta-Velasco F, Moran S.
    J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
    [Abstract] [Full Text] [Related]

  • 2. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
    Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M, Levine LS, Oberfield SE.
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
    [Abstract] [Full Text] [Related]

  • 3. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome.
    Alpañés M, Luque-Ramírez M, Martínez-García MÁ, Fernández-Durán E, Álvarez-Blasco F, Escobar-Morreale HF.
    Fertil Steril; 2015 Mar; 103(3):795-801.e2. PubMed ID: 25585504
    [Abstract] [Full Text] [Related]

  • 4. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC, Rizos D, Valsamakis G, Deligeoroglou E, Grigoriou O, Chrousos GP, Creatsas G, Mastorakos G.
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [Abstract] [Full Text] [Related]

  • 5. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
    Singh S, Akhtar N, Ahmad J.
    Diabetes Metab Syndr; 2012 Mar; 6(4):207-11. PubMed ID: 23199540
    [Abstract] [Full Text] [Related]

  • 6. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome.
    Ardawi MS, Rouzi AA.
    Fertil Steril; 2005 Jun; 83(6):1708-16. PubMed ID: 15950640
    [Abstract] [Full Text] [Related]

  • 7. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G.
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [Abstract] [Full Text] [Related]

  • 8. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X, Lin JF.
    Zhonghua Yi Xue Za Zhi; 2005 Dec 07; 85(46):3266-71. PubMed ID: 16409817
    [Abstract] [Full Text] [Related]

  • 9. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T, Dehghan-Kooshkghazi M.
    Gynecol Endocrinol; 2003 Feb 07; 17(1):51-6. PubMed ID: 12724019
    [Abstract] [Full Text] [Related]

  • 10. DHEA, DHEAS and PCOS.
    Goodarzi MO, Carmina E, Azziz R.
    J Steroid Biochem Mol Biol; 2015 Jan 07; 145():213-25. PubMed ID: 25008465
    [Abstract] [Full Text] [Related]

  • 11. Ovarian hyperandrogenism in adolescents and young women with type I diabetes is primarily related to birth weight and body mass index.
    Bizzarri C, Benevento D, Ravà L, Patera IP, Schiaffini R, Ciampalini P, Giannone G, Cappa M.
    Fertil Steril; 2011 Dec 07; 96(6):1497-1502.e1. PubMed ID: 21982726
    [Abstract] [Full Text] [Related]

  • 12. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
    Yilmaz SA, Kerimoglu OS, Pekin AT, Incesu F, Dogan NU, Celik C, Unlu A.
    Eur J Obstet Gynecol Reprod Biol; 2014 Sep 07; 180():56-60. PubMed ID: 25020276
    [Abstract] [Full Text] [Related]

  • 13. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
    Yildiz BO, Yarali H, Oguz H, Bayraktar M.
    J Clin Endocrinol Metab; 2003 May 07; 88(5):2031-6. PubMed ID: 12727950
    [Abstract] [Full Text] [Related]

  • 14. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
    Tziomalos K, Katsikis I, Papadakis E, Kandaraki EA, Macut D, Panidis D.
    Hum Reprod; 2013 Mar 07; 28(3):785-93. PubMed ID: 23315058
    [Abstract] [Full Text] [Related]

  • 15. Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance.
    Patlolla S, Vaikkakara S, Sachan A, Venkatanarasu A, Bachimanchi B, Bitla A, Settipalli S, Pathiputturu S, Sugali RN, Chiri S.
    Gynecol Endocrinol; 2018 Mar 07; 34(3):238-242. PubMed ID: 29068242
    [Abstract] [Full Text] [Related]

  • 16. [Insulin resistance and serum concentrations of ovarian and adrenal androgen in obese women without additional disease and with policystic ovary syndrome].
    Olszanecka-Glinianowicz M, Banaś M, Zahorska-Markiewicz B, Kuglin D, Mokrzycka J, Mentel A.
    Endokrynol Pol; 2005 Mar 07; 56(6):921-6. PubMed ID: 16821212
    [Abstract] [Full Text] [Related]

  • 17. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
    Lerchbaum E, Schwetz V, Giuliani A, Pieber TR, Obermayer-Pietsch B.
    Fertil Steril; 2012 Nov 07; 98(5):1318-25.e1. PubMed ID: 22835450
    [Abstract] [Full Text] [Related]

  • 18. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism.
    Castelo-Branco C, Steinvarcel F, Osorio A, Ros C, Balasch J.
    Gynecol Endocrinol; 2010 Oct 07; 26(10):736-42. PubMed ID: 20569105
    [Abstract] [Full Text] [Related]

  • 19. Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome.
    Panidis D, Rousso D, Koliakos G, Kourtis A, Katsikis I, Farmakiotis D, Votsi E, Diamanti-Kandarakis E.
    Fertil Steril; 2006 Jun 07; 85(6):1778-83. PubMed ID: 16650418
    [Abstract] [Full Text] [Related]

  • 20. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome.
    Puurunen J, Piltonen T, Jaakkola P, Ruokonen A, Morin-Papunen L, Tapanainen JS.
    J Clin Endocrinol Metab; 2009 Jun 07; 94(6):1973-8. PubMed ID: 19318449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.